Temozolomide is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 857   Edition : 37  

  ►   Brandname : Temodal
  ►  Strength : Injection with

Reference of this Medicine for its Strength can be taken from   Book : Martindale    Page : 857   Edition : 37  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral, IV
Reference :-   Book : Martindale    Page : 857   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Newly diagnosed glioblastoma multiforme Oral / i.v 45 mg/m2 Dose: Given daily for 42 days. Treatment may be interrupted or stopped depending on toxicity. Complete blood counts should be monitored weekly. Four weeks after completing the concomitant phase, temozolomide monotherapy is begun at an oral dose of 150 mg/m2 once daily for 5 days of a 28-day cycle. In cycle 2, the dose is increased to 200 mg/m2 for 5 days, if toxicity allows. If the dose cannot be increased in cycle 2, it should not be increased in subsequent cycles. The dose used at cycle 2 is then given every 28 days, toxicity allowing. Up to 6 cycles of temozolomide monotherapy may be given.
2 Recurrent or progressive malignant gliomas Oral 200 mg/m2 o.d. Dose for adults previously untreated with chemotherapy for 5 days, repeated every 28 days. In patients who have received previous courses of chemotherapy the initial oral or intravenous dose is 150 mg/m2 once daily for 5 days, for the first cycle of therapy, but may be increased to 200 mg/m2 for subsequent courses if there is no haematological toxicity.
3 Metastatic malignant melanoma Oral 200 mg/m2 o.d. Dose: given daily for 5 days every 28 days

Ref :-  Book : Martindale    Page : 857   Edition : 37   Martindale    Page : 858   Edition : 37  



Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, that recurs or progresses after standard therapy 3 Year

Ref :- Book : Martindale    Page : 858   Edition : 37  
►  Side Effect : Nausea, Vomiting, Constipation, Diarrhoea, Anorexia, Alopecia, Fatigue, Headache, Rashes, Convulsions, Insomnia, Somnolence, Anxiety, Depression, Confusion, Dizziness, Hemiparesis, Aphasia, Dysphonia, Peripheral neuropathy, Paraesthesia, Neurological and/or speech disorders, Tremor, Concentration or memory impairment, Visual field defect, Blurred Vision, Diplopia, Hearing impairment, Tinnitus, Deafness, Haemorrhage, Deep venous thrombosis, Peripheral oedema, Pulmonary embolism, Dyspnoea, Coughing, Dry skin, pruritus, Arthralgia, Myalgia, Urinary incontinence, Fever, Pain, Dysgeusia, Liver enzyme values may increase, Hyperglycaemia, Cushingoid disorders, Intestinal pneumonitis
Ref :-   Book : Martindale    Page : 857   Edition : 37.  

►  Drug Interaction : Drug interaction of Temozolomide is with Valproic acid(sodium valproate)
Ref :-   Book : Martindale    Page : 857   Edition : 37.  


  ►    Mechanism of Drug Drug Interaction :  Valproic acid decreases oral clearance of temozolomide by about 5 %
Ref :-   Book : Martindale    Page : 857   Edition : 37.  


►  Contraindication : Pregnancy
Ref :-   Book : Martindale    Page : 857   Edition : 37.  
  ►  Mechanism of Action :   Temozolomide is a prodrug that is converted to 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC). It is covalently bind DNA, often cross-link to DNA or associated Proteins. Ref: Martindale pg no 857 ed 37.
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 696   Edition : 3.  

Pathway of DIETARY Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA Angeer with Another pathwayAnother pathway.   Angeer with Another pathwayAnother pathway.  

  ►  Pathway with its reference as follows :-
  • coumarin play important role in inhibition of cancer cell growth. --- ( Yin, S., Wei, W., Jian, F., & Yang, N. (2013). Therapeutic Applications of Herbal Medicines for Cancer Patients. Evidence-Based Complementary And Alternative Medicine, 2013, 1-15 )
  • 6-o-acyl-beta-d-glucosyl-beta-sitosterols.found in fig or anjeer have anticancer property. --- (Joseph, Baby. "Pharmacognostic And Phytochemical Properties Of Ficus Carica Linn –An Overview". International Journal of PharmTech Research 3.1 (2017): 08-12,. Print. )
  • 6-o-acyl-beta-d-glucosyl-beta-sitosterols.found in fig or anjeer have anticancer property. --- (Joseph, Baby. "Pharmacognostic And Phytochemical Properties Of Ficus Carica Linn –An Overview". International Journal of PharmTech Research 3.1 (2017): 08-12,. Print. )

  •   ►  URL --
  • http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727181/ .
  • http://sphinxsai.com/Vol.3No.1/pharm_jan-mar11/pdf/JM11(%20PT=03)%2008-12.pdf .

  • DIETARY Substance Interactions


    ​   ► This Medicine interact with :- NA



    ContraIndication DIETARY Substance


    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   Renal
    Ref :-   Book : Martindale    Page : 857   Edition : 37.  

    ►    Plasma Half-life :   Min value :-   1.8 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 857   Edition : 37.  

    ►    Peak Plasma Concentration :   Min value :-   0.5 hour,    Max value :-   1.5 hour.  
    Ref :-   Book : Martindale    Page : 857   Edition : 37.